Previous close | 1.7300 |
Open | 1.7500 |
Bid | 1.7200 x 400 |
Ask | 1.7600 x 200 |
Day's range | 1.7200 - 1.7700 |
52-week range | 0.9800 - 9.9300 |
Volume | |
Avg. volume | 167,156 |
Market cap | 58.152M |
Beta (5Y monthly) | 0.24 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
In this piece, we will take a look at these stocks under $10 are poised to explode. If you want to skip our introduction to these tricky stocks, jump to These 5 Stocks Under $10 Are Poised To Explode. The US equity markets remain on track for a strong finish in 2023 as major indices […]
Reneo (RPHM) loses 83% following the failure of the mid-stage pivotal study of its only pipeline candidate, mavodelpar, to treat primary mitochondrial myopathies in adults. It cuts the workforce by 70%.
Reneo Pharmaceuticals Inc (NASDAQ: RPHM) shares are sinking after the company released data from its pivotal STRIDE Phase 2b study of mavodelpar in adult patients with primary mitochondrial myopathies (PMM), a group of mitochondrial diseases that cause prominent muscular problems. The study did not meet its primary efficacy or secondary efficacy endpoint. The trial's primary efficacy endpoint was the change from baseline in the distance walked during the 12-minute walk test (12MWT) at week 24. T